Objective: We determined the plasma protein C and coagulation factor X activities, prothrombin, fibrinogen and soluble fibrin monomer complex (SFMC) content and performed the haemostatic screening coagulation time tests under acute ischemic stroke patients with or without type 2 diabetes mellitus, as well as evaluated the significance of biochemical haemostatic markers as predictors of mortality in stroke regardless of diabetes presence. Methods: The baseline data were collected from 87 patients during the admission. Neurological disturbances were assessed using the NIH stroke scale. The functional outcome was estimated using Barthel index. All patients underwent fibrinogen and SFMC (gravimetric methods), prothrombin level (ELISA), plasma protein C and coagulation factor X activity assessment, haemostatic screening coagulation time tests with coagulation analyzer, glucose and glycosylated hemoglobin content and BMI (body mass index) measurements. Results: The conducted research had established the changes of fibrinogen and SFMC levels in both investigated patient groups comparing to the control. The protein C activity was found to be significantly decreased in blood of patients with ischemic stroke with and without diabetes. There were differences in factor X activity change in patients with stroke only comparing with patients with diabetes and stroke and high level of this parameter as well as the increase in SFMC can be regarded as death predictors of stroke independently of diabetes mellitus presence. Conclusion: Among ischemic stroke patients with type 2 diabetes mellitus the differences were more significant for all Time tests of the coagulation cascade, but deviations of haemostatic biochemical markers were more pronounced in ischemic stroke patients without diabetes mellitus.
Abstract-Introduction:The estіmated number of people with diabetes worldwide in 2015 is 415 million persons, up to 91% of adults hadtype 2 diabetes and the crude incidence of stroke among patients with diabetes of the 2 nd type can be more than 3 times that in the general population. It is known platelet activation and aggregation are critical in the pathogenesis of acute ischemic cerebrovascular diseases. Thus to examine the evidence of platelet functioning such as platelet count,aggregation in response to ADP, coagulation von Willebrand factor and serotonin content, monoamine oxidase (MAO) activity in the blood of patients with ischemic stroke and with ischemic stroke complicated with the 2 nd type diabetes are the aim of the present study. Methods: The platelet aggregation was assayed for photo-optical aggregometer, von Willebrand factor was determined by Elisa, serotonin determination included ion-exchange chromatography and fluorescence spectrophotometry. Determination of monoamine-oxidase serum activity was spectophotometry. Results: The investigation has shown an increase of serotonin and Von Willebrand factor blood content in both groups of patients with ischemic stroke andtype 2 diabetes and stroke alone compared with the values of the control group. The monoamine oxidase activity and platelet count were reduced in blood of patients with diabetes of the 2 nd type with ischemic stroke against to the values from the group of healthy donors. Platelet aggregation in response to ADP increased under the investigated pathologies. Conclusions: These obtained data suggested a significant imbalance in vascular platelet element of hemostasis under the ischemic stroke and amplification of negative changes under the stroke with the 2 nd type diabetes.
Diabetes is one of the generally accepted factors of acute cerebral blood flow disorders. Numerous studies have shown involvement of many factors in the pathogenesis of diabetic cerebral disorders, the most important of which are the metabolic changes, including endotoxication. The aim of this study was to measure the endotoxication parameters and total protein and albumin contents in the blood of patients with ischemic stroke and patients with stroke complicated by type 2 diabetes. Also the average sex, age of the patients, body mass index (BMI) and blood glucose and lipoproteins levels, different disease complication presents and NIH Stroke Scale with Barthel index were determined. The investigation had shown that patients with ischemic stroke, including complicated by insulin independent diabetes, were characterized by hypoproteinemia with the absence of marked changes of albumin content. The middle mass molecule (MSM) and oligopeptide contents revealed the presence of endogenous intoxication. These parameters, exceeding the control by 1.5 times, were high independently of hyperglycemia presence. The results also allowed to establish differences in BMI, hyperlipoproteinemia and increasing of NIHSS in patients with ischemic stroke and diabetes mellitus type 2 comparing with stroke alone. Thus, the development of ischemic stroke separately and under conditions of type II diabetes was characterized by increasing rates of endotoxication (middle mass molecule and oligopeptides contents) in the blood of patients, that with hypoproteinemia and hyperlipidemia may cause the secondary pathobiochemical changes in the head brain cells and mediate the negative effects of acute disorders of cerebral blood circulation.
The influence of a new enterosorbent-enterosgel on the immune and autoimmune process in the dynamics of ischemic heart disease and the possibilities of endogenic intoxication decrease using the given drug are estimated. The use of enterosgel made it possible to get the high therapeutic hypolipidemic and autoimmunocorrecting effect in patients with ischemic heart disease, expressed in the improvement of the state - the decrease of the frequency of stenocardia making it case of peace and effort making it possible to decrease daily nitroglycerine dose.
Matrix metalloproteinases (MMP) are a family of zinc-dependent endopeptidases, capable of degrading all the molecular components of extracellular matrix. A class of metalloproteinases–gelatinases, which includes gelatinase A or MMP-2 (72 kDa) and gelatinase B or MMP-9 (92 kDa) has been shown to play critical roles in a number of acute and chronic pathological processes, in particular, cardiovascular diseases. For these reasons gelatinasesobtained a great interest as potential non-invasive biomarkers in providing useful clinical information in stroke diagnosis and therapy. In present study we have analyzed the content of MMP-9 and MMP-2 in serum samples of patients with ischemic stroke alone and ischemic stroke complicated by diabetes mellitus type II, as well as the enzymatic activities presented in blood serum. It has been established that the acute phase of ischemic stroke is accompanied by the significant change of the content of investigated metalloproteinases in the blood serum. The obtained results demonstrated thatblood serum content of MMP-2 is significantly higher than content of MMP-9.The changes of the content of MMP-2 and MMP-9 were more pronounced in the group of patients with ischemic stroke and diabetes mellitus type 2 comparing with the results of patients with ischemic stroke alone.For analysis of forms of gelatinases the gelatine zymographytechnique was applied. This is a sensitive and simplemethodwhich allows to measure the relative amounts of active and inactive enzymes in body fluids and tissue extracts. The serum samples patients with stroke alone and complicated by diabetescontained two prominent gelatinolyticbands corresponding to monomeric proMMP-9 (92 kDa), proMMP-2 (72 kDa)active MMP-9 (85 kDa), MMP-2 (67 kDa)and some additional bands migrating above 100 kDa. By contrast, the healthy serum samplesdisplayed only the 92 and 72 kDa proforms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.